论文部分内容阅读
[目的]探讨索拉非尼联合表阿霉素对乳腺癌MCF-7细胞的增殖抑制作用。[方法]绘制MCF-7细胞生长曲线并在第14d检测其体外克隆形成率;MTT法测定72h时索拉非尼及表阿霉素单用与联用对MCF-7细胞的增殖抑制率。[结果]细胞生长曲线显示MCF-7细胞第1~4d生长速度较快,第4d后生长速度减慢,第10d后生长趋于停滞;第14dMCF-7细胞的克隆形成率为37.2%。在72h时间点,索拉非尼及表阿霉素单药对MCF-7均有抑制作用,两药联合则为协同或相加作用。[结论]索拉非尼和表阿霉素对乳腺癌MCF-7细胞增殖有抑制作用,联合用药表现出协同或相加作用。
[Objective] To investigate the inhibitory effect of sorafenib combined with epirubicin on the proliferation of breast cancer MCF-7 cells. [Method] The growth curve of MCF-7 cells was drawn and the colony formation rate was detected on the 14th day. The inhibition rate of sorafenib and epirubicin alone or in combination on MCF-7 cells was determined by MTT assay. [Result] The cell growth curve showed that the growth rate of MCF-7 cells was faster from the first day to the fourth day, the growth rate was slowed down after the fourth day, and the growth tended to stagnate after the 10th day. The clonogenic rate of MCF-7 cells on the 14th day was 37.2%. At the 72h time point, sorafenib and epirubicin monotherapy had an inhibitory effect on MCF-7, and the combination of the two drugs was synergistic or additive. [Conclusion] Sorafenib and epirubicin can inhibit the proliferation of MCF-7 breast cancer cells, and the combination therapy shows a synergistic or additive effect.